Europeiska unionen - svenska - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenter för dermatit, med undantag av kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - bältros (herpes zoster) - vacciner - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. användning av shingrix bör ske i enlighet med officiella rekommendationer.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

kyowa kirin holdings b.v. - testosteron - gel - 2 % - butylhydroxitoluen hjälpämne; propylenglykol hjälpämne; testosteron 20 mg aktiv substans; etanol, vattenfri hjälpämne - testosteron

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

eli lilly sweden ab - testosteron - kutan lösning - 30 mg/1.5 ml - etanol, vattenfri hjälpämne; testosteron 30 mg aktiv substans - testosteron

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laboratoires besins international - testosteron - transdermal gel - 50 mg - etanol, vattenfri hjälpämne; testosteron 50 mg aktiv substans - testosteron

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

endo ventures limited - testosteron - transdermal gel - 50 mg - propylenglykol hjälpämne; testosteron 0,05 g aktiv substans; glycerol hjälpämne; etanol, vattenfri hjälpämne - testosteron

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medartuum ab - testosteron - gel - 50 mg - etanol, vattenfri hjälpämne; testosteron 0,05 g aktiv substans; glycerol hjälpämne; propylenglykol hjälpämne - testosteron

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - testosteron - gel i dospåse - 50 mg - etanol, vattenfri hjälpämne; testosteron 50 mg aktiv substans - testosteron

Europeiska unionen - svenska - EMA (European Medicines Agency)

roche registration ltd. - nelfinavir - hiv-infektioner - antivirala medel för systemisk användning - viracept är indicerat vid antiretroviral kombinationsbehandling av hiv-1-infekterade, vuxna, ungdomar och barn som är tre år och äldre. i proteas-hämmare (pi)-erfarna patienter, val av nelfinavir bör baseras på individuella viral resistens testning och behandling historia.

Europeiska unionen - svenska - EMA (European Medicines Agency)

merck sharp & dohme b.v. - varicella-zostervirus (levande, dämpad) - herpes zoster; immunization - virala vacciner - zostavax är indicerat för förebyggande av herpes zoster ('zoster' eller bältros) och herpes-zoster-relaterad post-herpetic neuralgi. zostavax är indicerat för vaccination av personer 50 år eller äldre.